Genomics England Adopts Illumina’s BaseSpace Variant Interpreter for Cancer
June 26 2017 - 3:01AM
Business Wire
Illumina becomes primary vendor of tumor
variant interpretation and reporting software for pioneering
population sequencing project
Illumina, Inc. (NASDAQ:ILMN) and Genomics England announced
today that Illumina is the primary variant interpretation and
reporting software vendor for tumor and matched normal samples
characterized as part of the 100,000 Genomes Project.
In a little over a year since Illumina announced the
Bioinformatics and Clinical Interpretation Partnership with
Genomics England, the partnership has now set
unified standards for data and
analysis practices using BaseSpace Variant
Interpreter software for tumor variant review.
In the coming months, Genomics England will be expanding the use
of BaseSpace Variant Interpreter for cancer to all NHS Genomic
Medicine Centers, and Illumina will be removing the ‘Beta’ status
from its software offering, and formally launching it for public
release later this summer.
"We are very pleased to be enabling cutting-edge variant
interpretation and precision genomics for the NHS in cancer,” said
Garret Hampton, EVP Clinical Genomics Group at Illumina. “This is a
major milestone for our population sequencing efforts, and
demonstrates Illumina's commitment to developing software that
delivers on the promise of transformative healthcare through
sequencing."
Sir John Chisholm, Executive Chair at Genomics England said: “We
believe that whole genome sequencing will underpin the future of
cancer care – providing greater understanding of the disease and a
fuller prognostic picture for patients. Illumina’s variant
interpretation and reporting software will enable us to deliver
better insights from the 100,000 Genomes Project. We are delighted
to be working with Illumina alongside our other delivery partners
to drive forward genomic research and support our ambitions of
transforming NHS patient care.”
BaseSpace Variant Interpreter (Beta) enables researchers to
perform rapid annotation, filtering, and interpretation of genomic
data. Its user-friendly, efficient variant-to-report workflow helps
summarize findings into structured reports within a software
framework focused on data security, compliance, and operational
efficiency.
About Illumina, Inc.
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical, and applied markets.
Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture, and other emerging
segments. To learn more, visit www.illumina.com and
follow @illumina.
Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties. Examples of forward-looking statements
include, but are not limited to, statements we make regarding the
expected availability dates for new products and services
and FDA submission dates and intentions for certain
products and services. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements include challenges inherent in developing,
manufacturing, and launching new products and services, and the
other factors that are detailed in our filings with
the Securities and Exchange Commission, including our most
recent filings on Forms 10-K and 10-Q, or in information disclosed
in public conference calls, the date and time of which are released
beforehand. We do not intend to update any forward-looking
statements after the date of this release.
About Genomics England
Genomics England is a company owned by the Department of Health
and was set up to deliver the 100,000 Genomes Project. This
flagship project will sequence 100,000 whole genomes from NHS
patients and their families.
Genomics England has four main aims:
- to bring benefit to patients
- to create an ethical and transparent
programme based on consent
- to enable new scientific discovery and
medical insights
- to kickstart the development of a UK
genomics industry
The project is focusing on patients with rare diseases, and
their families, as well as patients with common cancers. For more
information visit www.genomicsengland.co.uk.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170626005362/en/
Investors:Illumina, Inc.Rebecca Chambers,
858-255-5243ir@illumina.comMedia:Illumina, Inc.David
Robertson, +44 (0)1223 824909Europe, Middle East, and
Africapr@illumina.comorIllumina, Inc.Jen Carroll,
858-882-6822pr@illumina.comorGenomics EnglandKatrina Nevin-Ridley,
0207 882 6493Director of
Communicationskatrina.nevin-ridley@genomicsengland.co.uk@GenomicsEngland
#genomes100k
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024